Researchers from the EuroPMP COST Action have recently published a new article looking at the antiproliferative activity of vorinostat in PMP-like cell lines. Members from Greece (Christiana Mantzourani and George Kokotos) and Finland (Pirjo Nummela and Ari Ristimäki) collaborated on this project to shed new light on the potential use of antitumor agents to treat pseudomyxoma peritonei. George notes:
“We have shown that one of these new analogs showed antiproliferative activity against two colon cancer cell lines genetically resembling pseudomyxoma peritonei (PMP), namely HCT116 GNAS R201C/+ and LS174T (IC50 0.6 and 1.4 μМ, respectively) with potency slightly better than vorinostat (IC50 1.1 and 2.1 μМ, respectively).”
We congratulate Finland and Greece on their successful collaborations thus far. Their article may be read on Elsevier’s website.